Furthermore, in the setting of the unique mutational landscape of ALM and relatively low frequency of BRAF mutations, the efficacy of BRAF and MEK inhibitors has been more limited in patients with ALM [14], although there have been multiple reports of benefit of c-KIT inhibitors in KIT mutated ALM [69]. Here, KIT is linked to acral lentiginous melanoma.